TOP 10 MYTHS ABOUT MS
Biogen's New Multiple Sclerosis Pill Tecfidera Sales: $192 Million.
FDA Approves New Drug for Major Depression
Salt a Culprit in Autoimmune Disease?
Patient Death Likely Unrelated to Multiple Sclerosis DrugWall Street Journal-Biogen Idec Inc. (BIIB) said Monday that a patient who had been taking itsmultiple sclerosis drug Tecfidera had died but that, at this time, it doesnot appear the treatment caused the death. The patient was not takingTecfidera at the time of death
Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years
The case for vitamin D supplementation in multiple sclerosis
Potential therapeutic mechanism of K+ channel block for MS
Sodium imaging as a marker of tissue injury in patients with multiple sclerosis
Escondido Woman Takes A Different Path In Her Fight Against Multiple Sclerosis
Barkingside mum overcomes multiple sclerosis and son's stroke to set up business
Gray Matter Pathology in MS: Neuroimaging and Clinical Correlations.
Quantifying gait impairment using an instrumented treadmill in people with multiple sclerosis: Conclusion. The instrumented treadmill may be an effective tool in assessing ambulation capabilities of people with MS.
Association between multiple sclerosis risk-associated SNPs and relapse anddisability - a prospective cohort study
Combining HLA-DR risk alleles and anti-Epstein-Barr virus antibody profiles to stratify multiple sclerosis risk
Comparison of deep gray matter lesions on magnetic resonance imaging among adults with acute disseminated encephalomyelitis, multiple sclerosis, and neuromyelitis optica
Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration
Prevalence of Radiologically Isolated Syndrome and White Matter Signal Abnormalities in Healthy Relatives of Multiple Sclerosis Patients
The clinico-radiological paradox in multiple sclerosis: novel implications of lesion size
No evidence for a role of rare CYP27B1 variants in Austrian multiple sclerosis patients
Biogen's New Multiple Sclerosis Pill Tecfidera Sales: $192 Million.
FDA Approves New Drug for Major Depression
Salt a Culprit in Autoimmune Disease?
Patient Death Likely Unrelated to Multiple Sclerosis DrugWall Street Journal-Biogen Idec Inc. (BIIB) said Monday that a patient who had been taking itsmultiple sclerosis drug Tecfidera had died but that, at this time, it doesnot appear the treatment caused the death. The patient was not takingTecfidera at the time of death
Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years
The case for vitamin D supplementation in multiple sclerosis
Potential therapeutic mechanism of K+ channel block for MS
Sodium imaging as a marker of tissue injury in patients with multiple sclerosis
Escondido Woman Takes A Different Path In Her Fight Against Multiple Sclerosis
Barkingside mum overcomes multiple sclerosis and son's stroke to set up business
Gray Matter Pathology in MS: Neuroimaging and Clinical Correlations.
Quantifying gait impairment using an instrumented treadmill in people with multiple sclerosis: Conclusion. The instrumented treadmill may be an effective tool in assessing ambulation capabilities of people with MS.
Association between multiple sclerosis risk-associated SNPs and relapse anddisability - a prospective cohort study
Combining HLA-DR risk alleles and anti-Epstein-Barr virus antibody profiles to stratify multiple sclerosis risk
Comparison of deep gray matter lesions on magnetic resonance imaging among adults with acute disseminated encephalomyelitis, multiple sclerosis, and neuromyelitis optica
Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration
Prevalence of Radiologically Isolated Syndrome and White Matter Signal Abnormalities in Healthy Relatives of Multiple Sclerosis Patients
The clinico-radiological paradox in multiple sclerosis: novel implications of lesion size
No evidence for a role of rare CYP27B1 variants in Austrian multiple sclerosis patients
